Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Canada First to Receive New Treatment Option for Liver Cancer Patients

By Drug Discovery Trends Editor | December 8, 2016

BTG International Canada, a part of global specialist healthcare company BTG announced the commercial launch of DC Bead LUMI in Canada. The launch represents the first market commercialization of DC Bead LUMI in the world, with regulatory clearances and launches planned for additional markets worldwide.

BTG International Canada Inc. received Health Canada approval for DC Bead LUMI in August, 2016.

DC Bead LUMI is the first available radiopaque embolic drug-eluting bead that can be loaded with doxorubicin for the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer or with irinotecan for the treatment of malignant colorectal cancer metastasized to the liver (mCRC ).

Drug-eluting beads are used in trans-arterial chemoembolization (TACE), which is a minimally invasive liver cancer treatment.  Drug-eluting bead TACE combines the deliberate blocking of the blood supply to the tumour and delivery of a local, controlled, sustained dose of chemotherapy directly to the tumour.

DC Bead LUMI is a next generation development of DC Bead, the market leading drug-eluting embolic bead that has the potential to revolutionize the treatment of liver tumours.

The unique visibility of DC Bead LUMI helps optimize patient treatment by enabling real-time visible confirmation of bead location during and after the embolization procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE